Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- HRB +10.2%, BTI +0.8%, CPST +0.7%, CCE +0.7%, (reaffirmed outlook)
M&A news:
- BKD +11.2% (Zhonghong Zhuoye Group is getting closer to deal to acquire BKD, according to FT)
Other news:
- MBOT +12.8% (granted U.S. patent which covers a device for the prevention of shunt stenosis)
- SOL +7.9% (received a prelim proposal from Chairman and CEO Xianshou Li to acquire the co's manufacturing and LED distribution businesses and assume related indebtedness)
- ABIL +7.9% (stock continues to be volatile in pre-mkt activity)
- MVIS +7.1% (Microvision terminates at-the-market facility with IFS Securities)
- ALXN +4.5% (confirms it named BIIB's CFO Paul Clancy as its CFO effective July 31)
- BTX +3.8% (reports that, based on the analysis of top line data, the Renevia pivotal trial in Europe has met its primary endpoint)
- BLFS +3.5% (enters into a a supply agreement w/ Adaptimmune Therapeutics (ADAP))
- GNMK +2.2% (prices 6,382,978 shares of its common stock at $11.75 per share)
- EMR +0.9% (favorable commentary on last night's Mad Money)
- TSLA +0.9% (continued strength)
- WDC +0.9% (continued strength)
Analyst comments:
- NDRM +4.4% (upgraded to Outperform from Perform at Oppenheimer)
- QSR +1.1% (upgraded to Outperform from Perform at Oppenheimer)
- NVDA +0.7% (target raised to $171 from $165 at Goldman)
- MU +0.5% (Credit Suisse sees upside for May and August quarters)